Bayer's Job Cuts And Flat 2021 Sales Outlook Disappoint
But Bolt-On Pharma Acquisitions, Product Licensing, To Continue
Executive Summary
Licensing agreements and bolt-on acquisitions to strengthen its R&D pipeline are still in Bayer’s sights as the COVID-19 pandemic and currency devaluations have led to the need for job cuts and substantial cost savings at the big pharma company.